Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Collaborative Community Oncology Support for Therapy Management in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology Italy, Japan, Spain, United Kingdom Emerging Data and Unmet Needs in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)Release Date:Education Oncology All New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)Release Date:Education Oncology All Education in the Era of Emerging Hemophilia Therapy (Round 2)Release Date:Education Rare Disease USA Improving Actionable Biomarker Testing Through Technology-Enabled SolutionsRelease Date:Partner: Conquer Cancer, The ASCO FoundationQuality Improvement Oncology USA USP <797> Pharmaceutical Compounding-Sterile Preparations: Challenges and Special ConsiderationsRelease Date:Education Inflammation & Immunology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special PopulationsRelease Date:Research Inflammation & Immunology China Unmet Need and Emerging Data in Muscle Invasive Bladder Cancer (MIBC)Education Oncology USA Bridging the Inflammatory Dermatosis Care Divide with TeledermatologyRelease Date:Partner: The George Washington UniversityQuality Improvement Inflammation & Immunology USA Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) PathogensRelease Date:Research Inflammation & Immunology China Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research CollaborationRelease Date:Call for Collaborator(s) Vaccines France, Germany